Zacks Investment Research on MSN10 小时
GILD Stock Down on Report of Cut in HIV Prevention Spending
Shares of Gilead Sciences, Inc. GILD were down 2.47% after the Wall Street Journal reported that The Health and Human ...
Zacks Investment Research on MSN7 小时
Gilead Sciences (GILD) Suffers a Larger Drop Than the General Market: Key Insights
The most recent trading session ended with Gilead Sciences (GILD) standing at $105.87, reflecting a -1.53% shift from the previouse trading day's closing. This change lagged the S&P 500's daily loss ...
STAT15 小时
Biotech stocks get boost from Fed rate outlook
The Fed kept rates unchanged for now, a move that was widely expected. It did note, though, that “uncertainty around the ...
FierceBiotech19 小时
Fierce Biotech Layoff Tracker 2025: Elevation eliminates 70% of staff; bit.bio cuts 25% of ...
Story Jan. 10 - Shoreline Biosciences: The cell therapy biotech plans to let go of an undisclosed number of employees tied to a project with Gilead Sciences’ Kite Pharma. Story Jan. 9 - IGM ...
CNN9 小时
Exelixis, Inc.
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx ...
National Institute for Health and Care Excellence17 小时
In consultation: Guidance and quality standards
Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110] Draft guidance Technology appraisal guidance 27 March ...